Related Experiment Video
Updated: Oct 14, 2025

Analysis of Minerals Produced by hFOB 1.19 and Saos-2 Cells Using Transmission Electron Microscopy with Energy Dispersive X-ray Microanalysis
Published on: June 24, 2018
FGF23 and Hypophosphatemic Rickets/Osteomalacia
Yuichi Takashi1, Daiji Kawanami1, Seiji Fukumoto2
1Department of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine, Fukuoka, Japan.
X-linked hypophosphatemia and tumor-induced osteomalacia involve impaired phosphate reabsorption due to excess FGF23. New treatments targeting FGF23 show promise, but long-term effects require further study.
Area of Science:
- Endocrinology
- Nephrology
- Genetics
Background:
- X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) are characterized by hypophosphatemia and defective renal phosphate handling.
- Current management for XLH and inoperable TIO involves phosphate and active vitamin D supplementation.
- Surgical tumor resection is the primary treatment for TIO.
Purpose of the Study:
- To review the pathogenesis of XLH and TIO.
- To discuss emerging therapeutic strategies for these conditions.
Main Methods:
- Literature review focusing on pathogenesis and treatment of XLH and TIO.
- Analysis of recent clinical findings on FGF23-targeting therapies.
Main Results:
- Elevated Fibroblast Growth Factor 23 (FGF23) production is a common pathogenic factor in XLH and TIO.
- Burosumab, an anti-FGF23 monoclonal antibody, is approved for certain hypophosphatemic diseases.
- The efficacy and indications for burosumab vary globally.
Conclusions:
- Targeting excessive FGF23 activity represents a novel therapeutic approach for hypophosphatemic disorders.
- Further research is essential to establish the long-term safety and efficacy of burosumab.
More Related Videos
Related Concept Videos
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
What is the Skeletal System?
Inborn Errors of Metabolism
Introduction to Electrolytes
Role of Sodium
One...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...

